Phytopharm Share Discussion Threads

[madmonkflin] 18/10/2011 08:06

great on Teva - weren't they trialling drugs from 3 companies at the same time including cogane?

[mrsapeslaptop] 17/10/2011 22:16

useful research link

[mrsapeslaptop] 17/10/2011 22:04

another one bites the dust.

[mrsapeslaptop] 13/10/2011 15:32

dr biotech. I made my money off several that you mention. plus sar, summ, pjp my only big loss was sln when it was sr pharma, but im buying that the moment. question of timing. still adding slowly here

[dr biotech] 12/10/2011 13:21

Mrs A - Unfortuantely passing a PI test is not up to much. Basically that means its not toxic.

PII is more interesting - small number of patients and generally monitors for toxicity and efficacy.

PIII is statisical proof of efficacy

Each stage takes forever.

I've seen (and lost large amounts) a lot of UK bios (AZM/ARA/XEN/RGT/CEN/SCO/AKT/OXB/CANTAB/OGS others) that had products get through the first two stages only to fall at the final hurdle. Its only CCH/CAT that got anywhere. I do still hold some of these that I hope to one day lay off as a tax loss, but I have long since given up hope that they will hit the big time.

Good luck though, I want them to succeed

[madmonkflin] 12/10/2011 12:56

Any news on ALS yet?

[mrsapeslaptop] 04/10/2011 07:37

Phytopharm is Awarded a Technology Strategy Board Grant to Support the Development of Myogane(TM) in Glaucoma

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that it has been awarded a grant by the Technology Strategy Board to provide funding to support the evaluation of Myogane(TM) in an in vivo preclinical model of glaucoma.

Myogane(TM) has the potential to be a neuro-protectant treatment of glaucoma. Glaucoma is a neurodegenerative disease of the eye affecting 60 million people and is the second leading cause of blindness worldwide. Current treatments of glaucoma are predominantly targeted at reducing intra ocular pressure within the eye, however the remains a major unmet medical need for treatments which can slow the underlying neurodegenerative disease process.

Myogane(TM) has demonstrated neuro-protective and neuro-restorative effects in a range of neuronal cell types including retinal ganglion cells, which are the cells affected in glaucoma. Myogane(TM) exhibits it's effect via the modulation of neurotrophic factors, naturally occurring proteins which protect and promote the growth of neurones and which have been shown to be effective in protecting against neurodegeneration in a number of models of glaucoma.

[madmonkflin] 29/9/2011 16:44

It is in phase II and I'm hoping I don't get a double whammy having had shares in renovo before now (and thats @ucked).

[mrsapeslaptop] 29/9/2011 16:16

well its already passed Phase 1 trials

[dr biotech] 29/9/2011 16:10

Well it'd be nice it works as MND is largely unresponsive to treatments. A former prof from my uni had this and died after two years of rather unpleasant effects. As always though its somewhat unlikely to pass clinical trials.

[mrsapeslaptop] 29/9/2011 09:33

as soon as we have the gold standard research (due this qtr). we are in a position to licence this. we can wait a little bit longer

[stoney4th] 29/9/2011 07:42

RNS Number : 1300P

Phytopharm PLC
29 September 2011

Cogane(TM) - European Commission Grants Orphan Drug status for treatment of ALS

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that the European Commission has granted Orphan Drug status to Cogane(TM) (PYM50028) for the treatment of amyotrophic lateral sclerosis (ALS).

The United States Food & Drug Administration (US FDA) granted Orphan Drug status to Cogane(TM) (PYM50028) for the treatment of amyotrophic lateral sclerosis (ALS) in July 2011

ALS, also known as Lou Gehrig's disease, is the most prevalent form of motor neurone disease, which generally strikes people between 40 and 60 years of age. It is characterised by progressive loss of motor neurones, which eventually leads to death. There is an urgent need for the development of new approaches to this devastating condition. It is estimated that the prevalence of ALS in Europe is 0.5--1.1 per 10,000. For a product to gain orphan drug status in Europe, the condition must affect less than 5 in 10,000 people in the member states.

As reported in the Company's Interim Results, Cogane(TM) has previously shown promising activity in preclinical in vitro and in vivo models of ALS. A study of Cogane(TM) in the genetic "gold standard" in vivo model of ALS is ongoing. This study has the support of the Motor Neurone Disease Association, a UK based charitable organisation, which has provided a grant to cover the costs of the study. Results from the study are expected in Q4 2011 and, if positive, offer the potential to support a rapid progression into clinical trials of ALS.

[mrsapeslaptop] 25/9/2011 22:35

fingers crossed. I do think this is a 20- 100* potential on the share price

[madmonkflin] 25/9/2011 20:56

Q4 2011 starts after next week so hopefully some feedback on ALS trials shortly...

[mrsapeslaptop] 29/8/2011 20:12

very little PI interest (large institutional holdings). and no major unexpected news for nearly the last 2 years.

They are just plodding on with the trial. ALS news will be interesting though (Q4 this year). If positive, and with the orphan drug status, I expect them to licence this for P2 trials (to diversify the risk). I would expect the share price to 4 or 5 times increase if this happened.

a share for the patient.

[algernon2] 29/8/2011 19:41

Whats going on here and why so quiet?

[baldeagle5] 22/8/2011 18:10

Here's hoping its positive MrsA!

[mrsapeslaptop] 20/8/2011 14:35

hi munch & baldeagle. we should see some news before XMAS around ALS suitability. shareprice not immune from the wider market it seems. hey ho.

[moneymunch] 18/8/2011 17:55

MsApe, the statement suggest's much poetential, and i intend to take up a position, just as soon as Summit confirm their first deal......which as you know, could happen anytime now!!! GL ;-)

[baldeagle5] 05/8/2011 19:02

MrsApe - amen to that looking at some moves today!

[mrsapeslaptop] 04/8/2011 20:19

an advantage of course of little PI Interest is no hot money heading for the exits.

[mrsapeslaptop] 01/8/2011 12:17

So reading in between the lines.

The company has said it will look to partner.

The Orphan status on ALS increases its value and suggests they are getting a licence package in place before the next study is available in Q4.

I would expect similar on Glaucoma also Q4.

I hope that they are already in early negotiations on both of these. That would enable a licencee to move rapidly into Phase 2 trials, generating sufficient milestone payments in time for the P2 Parkinsons completion.

Raising the possibility that PYM would be able to self fund P3/4 trials in PD by itself without needing a partner or further funding.

a scenario, but quite a likely one I think.